Schering Corporation

Merck Sharp + Dohme Corp.

Anesiva, Inc.

Christi L Parham

Kevin W Moore

Robert A Kastelein

Madaline Chirica

Nicholas J Murgolo

J Fernando Bazan

Daniel M Gorman

Terrill K McClanahan

Jeanine D Mattson

Theodore R Sana

Erin E Murphy

Jeffery Grein

Hirokazu Kurata

Naoko Arai

Chetan Savkoor

Kathleen M Smith

Leslie McEvoy

Jie Zhang

Rolf O Ehrhardt

Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.

Antagonists of IL-23P19 for treatement of atopic dermatitis

Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

Nucleic acids encoding TNF&#x3b3;

Mammalian receptor proteins DCRS5; methods of treatment

Nucleic acid encoding TNFx protein

Nucleic acids encoding DCRS5

Mammalian receptor protein DCRS5; methods of treatment

DCRS5 polypeptides

Mammalian receptor proteins DCRS5; method of treatment

Nucleic acids encoding mammalian, e.g., primate or rodent receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.

DIRS1 polypeptides

Method for raising or isolating an antibody to DCRS5

Mammalian receptor protein DCRS5;methods of treatment

The present invention concerns double-stranded NF-&#x3ba;B decoy oligodeoxynucleotide (NF-&#x3ba;B dsODN) molecules that contain a core sequence capable of specific binding to an NF-&#x3ba;B transcription factor. In a particular aspect, the invention concerns NF-&#x3ba;B decoy molecules that preferentially bind p50/p65 and/or cRel/p50 heterodimers over p50/p50 homodimers. In another aspect, the invention concerns NF-&#x3ba;B decoy molecules with improved binding affinity to p65.

NF-kappaB oligonucleotide decoy molecules

Growing community of inventors

Menlo Park, CA, United States of America

Christi L Parham